JOINT VENTURE WITH YAFO CAPITAL, LTD.
With the idea to have representatives for licensing transactions in Europe and in China, FCF Life Sciences formed a joint venture with Yafo Capital, Ltd. in 2019. Together, we form a unique team to address the needs of our European and Asian clients. Our aim is to facilitate and guarantee a smooth partnering process.
Facts on Yafo Capital, Ltd.
- Shanghai based advisory firm
- Established network and access to leading 200+ Pharma and MedTech companies in Asia
- Team of 20+ professionals with banking and healthcare background
- ~20 completed transactions within the last five years
ACCESS CHINA FORUM
Company presentations
0
Participants
0
Meeting requests
0
Assets presented
0
FCF co-organizes, together with its partner YAFO Capital, the “ACCESS CHINA Forum”, which will be held online 4x per year.
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable business development opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable business development opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.
UPCOMING EVENT
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2025 published
March 31, 2025
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2025”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of February 2025 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 6,893m (+14% vs. 2024)
- After a strong start in January with a 64% year-over-year increase, healthcare and life sciences funding in the U.S. has significantly slowed in February
- Biotech/Pharma received 51% of the total investment volume (EUR 3,543m) with immunology being the leading indication (26%)
- In February Eikon Therapeutics secured the highest transaction volume with EUR 337m, followed by Abridge with EUR 240m and Abcuro with EUR 193m
- Accelmed (United States) is the most active investor (by deal volume in 2025), followed by Y Combinator (United States) and F-Prime Capital (United States)
To access the full report, please click here.
